South Dakota Equity Partners

Property Meld is a property management maintenance solution based in Rapid City, South Dakota, established in 2014. The company offers a maintenance automation tool designed to streamline and simplify the property maintenance process. By integrating scheduling, tracking, and communication into a single platform, Property Meld facilitates coordination between multiple parties involved in property management. This innovative approach not only enhances operational efficiency but also aims to improve tenant retention rates, reduce costs, and maximize returns for its clients.

Query offers a browser-based platform that enhances the efficiency of security investigations by providing a unified search interface for disparate security data sources. This platform allows security teams to access and analyze data stored in various locations, including cloud services, third-party SaaS applications, and on-premises systems, without the need for data centralization. By delivering real-time insights and visual context, Query enables analysts to answer security-related questions effectively, streamlining their investigations and reducing operational costs.

Query offers a browser-based platform that enhances the efficiency of security investigations by providing a unified search interface for disparate security data sources. This platform allows security teams to access and analyze data stored in various locations, including cloud services, third-party SaaS applications, and on-premises systems, without the need for data centralization. By delivering real-time insights and visual context, Query enables analysts to answer security-related questions effectively, streamlining their investigations and reducing operational costs.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.

Nanopareil, LLC specializes in producing advanced separation modules made from functionalized nanofibers. Founded in 2011 and headquartered in Dakota Dunes, South Dakota, the company serves various industries, including biopharmaceuticals, biofuels, and water purification. Nanopareil's proprietary nanofiber filters utilize a randomly overlaid mat of electrospun nanofibers, offering a unique separation medium that enables both size-based and adsorptive separation. This innovative approach enhances process efficiencies and economics, making it particularly valuable for applications in biopharmaceutical production, water treatment, and air purification. By reducing processing times, minimizing waste, and decreasing the required volume of separation media, Nanopareil supports biomedical researchers in lowering costs and improving manufacturing processes. The company is a subsidiary of ProMetic BioSciences Ltd. as of September 2020.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.